In vivo liposomal delivery of PPARα/γ dual agonist tesaglitazar in a model of obesity enriches macrophage targeting and limits liver and kidney drug effects. The gene discussed is PPARA; the disease is obesity due to melanocortin 4 receptor deficiency.